Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

This study evaluated the short-term effects of canagliflozin and semaglutide, administered alone or in combination, on renal function, metabolic parameters, and systemic inflammatory markers in patients with early-stage DKD.

Why It Was Studied

Diabetic kidney disease (DKD) is a common complication of type 2 diabetes mellitus and an important cause of end-stage renal disease.

Metabolic dysfunction, albuminuria, and chronic low-grade inflammation characterize early DKD, leading to progressive renal impairment.

Who Took Part

The study group was 120 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

All participants were provided standard background care.

Treatment continued for 24 weeks.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of Semaglutide, giving a reference point.

A time span of 24 weeks appears in the methods.

The main renal outcomes were urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR).

Glycemic control, insulin resistance, lipid parameters, and inflammatory biomarkers (HbA1c, fasting glucose, HOMA-IR, TNF-α, IL-6, CRP) were considered as secondary outcomes.

Safety assessment was conducted using binary safety assessment.

What Was Measured

PubMed files the paper under topics including Canagliflozin, Semaglutide, Diabetic Nephropathies, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors and Hypoglycemic Agents.

Author keywords: Combination therapy, Early diabetic kidney disease, Inflammatory biomarkers, Metabolic parameters and Renal outcomes.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Semaglutide in 120 patients over 24 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Pakistan journal of pharmaceutical sciences), a journal based in Pakistan.

More context: the Semaglutide compound page, all human trials.